Regarding the PI3K/AKT/mTOR inhibitors, even if PIK3CA was the only gene more frequently altered in non‐IBC compared to IBC, its frequency of alteration was relatively high in IBC (21%), with many hotspot mutations. The gene discussed is MTOR; the disease is inflammatory breast carcinoma.